<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144401</url>
  </required_header>
  <id_info>
    <org_study_id>AS1374</org_study_id>
    <nct_id>NCT03144401</nct_id>
  </id_info>
  <brief_title>Preoperative vs. Postoperative Misoprostol in Elective Cesarean Section</brief_title>
  <official_title>Preoperative vs. Postoperative Misoprostol in Elective Cesarean Section: A Double-blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective double-blind placebo-controlled randomized clinical trial will be conducted
      at Ain-Shams University Maternity Hospital from April 2017 till October 2017. 120 women
      candidate foe elective cesarean section will receive preoperative sublingual 400 microgram of
      misoprostol, and another 120 women will receive postoperative sublingual 400 microgram of
      misoprostol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">February 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 12, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for extra uterotonics</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraoperative blood loss</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postpartum hemorrhage</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal outcome</measure>
    <time_frame>5 minutes</time_frame>
    <description>measured by APGAR score at 1 and 5 minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Preoperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) &quot;2 tablets&quot; and postoperative sublingual placebo&quot;2 tablets&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postoperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• Group no.2 will receive preoperative sublingual placebo &quot;2 tablets&quot; and postoperative sublingual 400 microgram of misoprostol (Sigma) &quot; 2 tablets&quot; .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>mesotac</description>
    <arm_group_label>Preoperative</arm_group_label>
    <arm_group_label>Postoperative</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet identical to the misoprostol tablet but without the active ingredient</description>
    <arm_group_label>Preoperative</arm_group_label>
    <arm_group_label>Postoperative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients booked for elective cesarean section.

          -  Singleton pregnancies.

          -  Full term pregnancies (GA 37- 42 Wks).

          -  Age (18-40 yrs).

          -  body mass index (BMI) (20-30(Kg/m2 .

        Exclusion Criteria:

          -  Contraindication to spinal anesthesia.

          -  Blood dyscrasias.

          -  Large fibroids.

          -  Multiple pregnancies.

          -  Overdistended uterus eg. Hydramnios.

          -  Pre-eclampsia.

          -  Marked maternal anemia (Preoperative hemoglobin &lt; 9 gm/dl).

          -  Previous history of PPH.

          -  Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or
             allergy to misoprostol.

          -  Placenta previa.

          -  Previous myomectomy.

          -  Extreme of BMI (&lt;20 or &gt;30 Kg/m2 ).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed S Sweed, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cesarean section</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>sublingual</keyword>
  <keyword>uterotonics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

